May 31, 2016

Novocure Receives IDE Approval to Initiate METIS Trial

Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer… Read More
learn more
May 31, 2016

Novocure Receives IDE Approval to Initiate METIS Trial

Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer… Read More
learn more
May 31, 2016

Novocure Receives IDE Approval to Initiate METIS Trial

Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer… Read More
learn more
May 23, 2016

Novocure Enrolls Last Patient in PANOVA Trial of Tumor Treating Fields Plus Chemotherapy in Advanced Pancreatic Cancer

The first cohort testing TTFields plus gemcitabine suggests improved survival and response rate compared to a historical control of gemcitabine alone The first cohort testing TTFields plus gemcitabine suggests improved survival and response rate compared to a historical control of gemcitabine alone May 23, 2016 07:30… Read More
learn more
May 23, 2016

Novocure Enrolls Last Patient in PANOVA Trial of Tumor Treating Fields Plus Chemotherapy in Advanced Pancreatic Cancer

The first cohort testing TTFields plus gemcitabine suggests improved survival and response rate compared to a historical control of gemcitabine alone The first cohort testing TTFields plus gemcitabine suggests improved survival and response rate compared to a historical control of gemcitabine alone May 23, 2016 07:30… Read More
learn more
May 23, 2016

Novocure Enrolls Last Patient in PANOVA Trial of Tumor Treating Fields Plus Chemotherapy in Advanced Pancreatic Cancer

The first cohort testing TTFields plus gemcitabine suggests improved survival and response rate compared to a historical control of gemcitabine alone The first cohort testing TTFields plus gemcitabine suggests improved survival and response rate compared to a historical control of gemcitabine alone May 23, 2016 07:30… Read More
learn more
May 19, 2016

Novocure Enrolls Last Patient in INNOVATE Trial Testing Tumor Treating Fields Plus Paclitaxel in Recurrent Ovarian Cancer

Trial tests safety and potential synergy between a taxane and TTFields in the treatment of recurrent ovarian cancer Trial tests safety and potential synergy between a taxane and TTFields in the treatment of recurrent ovarian cancer May 19, 2016 04:30 PM Eastern Daylight Time ST. HELIER,… Read More
learn more
May 19, 2016

Novocure Enrolls Last Patient in INNOVATE Trial Testing Tumor Treating Fields Plus Paclitaxel in Recurrent Ovarian Cancer

Trial tests safety and potential synergy between a taxane and TTFields in the treatment of recurrent ovarian cancer Trial tests safety and potential synergy between a taxane and TTFields in the treatment of recurrent ovarian cancer May 19, 2016 04:30 PM Eastern Daylight Time ST. HELIER,… Read More
learn more
May 19, 2016

Novocure Enrolls Last Patient in INNOVATE Trial Testing Tumor Treating Fields Plus Paclitaxel in Recurrent Ovarian Cancer

Trial tests safety and potential synergy between a taxane and TTFields in the treatment of recurrent ovarian cancer Trial tests safety and potential synergy between a taxane and TTFields in the treatment of recurrent ovarian cancer May 19, 2016 04:30 PM Eastern Daylight Time ST. HELIER,… Read More
learn more
May 18, 2016

Novocure Announces Presentation of Subgroup Analysis of PANOVA Data Showing Overall Survival Benefit of Tumor Treating Fields Plus Gemcitabine in Advanced Pancreatic Cancer Patients

Median overall survival exceeded 15 months in patients with locally advanced pancreatic cancer treated with TTFields therapy combined with gemcitabine Median overall survival exceeded 15 months in patients with locally advanced pancreatic cancer treated with TTFields therapy combined with gemcitabine Metastatic pancreatic cancer patients… Read More
learn more